PMC:3586680 / 79-241 JSONTXT

{"project":"test3","denotations":[{"id":"T61","span":{"begin":27,"end":30},"obj":"Protein"},{"id":"T43","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"testone","denotations":[{"id":"T21","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"bionlp-st-ge-2016-test-tees","denotations":[{"id":"T476","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T589","span":{"begin":150,"end":153},"obj":"CC"},{"id":"T588","span":{"begin":148,"end":149},"obj":"-RRB-"},{"id":"T587","span":{"begin":145,"end":148},"obj":"NNP"},{"id":"T586","span":{"begin":144,"end":145},"obj":"-LRB-"},{"id":"T585","span":{"begin":131,"end":143},"obj":"VB"},{"id":"T584","span":{"begin":128,"end":130},"obj":"TO"},{"id":"T583","span":{"begin":117,"end":127},"obj":"NN"},{"id":"T582","span":{"begin":114,"end":116},"obj":"TO"},{"id":"T581","span":{"begin":112,"end":113},"obj":","},{"id":"T580","span":{"begin":108,"end":112},"obj":"NN"},{"id":"T579","span":{"begin":105,"end":107},"obj":"IN"},{"id":"T578","span":{"begin":103,"end":104},"obj":","},{"id":"T577","span":{"begin":93,"end":103},"obj":"VB"},{"id":"T576","span":{"begin":90,"end":92},"obj":"TO"},{"id":"T575","span":{"begin":82,"end":89},"obj":"VBZ"},{"id":"T574","span":{"begin":78,"end":81},"obj":"CC"},{"id":"T573","span":{"begin":76,"end":77},"obj":"-RRB-"},{"id":"T572","span":{"begin":72,"end":76},"obj":"NNS"},{"id":"T571","span":{"begin":71,"end":72},"obj":"-LRB-"},{"id":"T570","span":{"begin":57,"end":70},"obj":"NNS"},{"id":"T569","span":{"begin":54,"end":56},"obj":"IN"},{"id":"T568","span":{"begin":46,"end":53},"obj":"VBN"},{"id":"T567","span":{"begin":35,"end":45},"obj":"RB"},{"id":"T566","span":{"begin":31,"end":34},"obj":"VBP"},{"id":"T565","span":{"begin":27,"end":30},"obj":"NN"},{"id":"T564","span":{"begin":16,"end":26},"obj":"NN"},{"id":"T563","span":{"begin":10,"end":15},"obj":"NNP"}],"relations":[{"id":"R276","pred":"compound","subj":"T563","obj":"T565"},{"id":"R277","pred":"compound","subj":"T564","obj":"T565"},{"id":"R279","pred":"auxpass","subj":"T566","obj":"T568"},{"id":"R280","pred":"advmod","subj":"T567","obj":"T568"},{"id":"R281","pred":"ROOT","subj":"T568","obj":"T568"},{"id":"R282","pred":"prep","subj":"T569","obj":"T568"},{"id":"R283","pred":"pobj","subj":"T570","obj":"T569"},{"id":"R284","pred":"punct","subj":"T571","obj":"T572"},{"id":"R285","pred":"appos","subj":"T572","obj":"T570"},{"id":"R286","pred":"punct","subj":"T573","obj":"T568"},{"id":"R287","pred":"cc","subj":"T574","obj":"T568"},{"id":"R288","pred":"conj","subj":"T575","obj":"T568"},{"id":"R289","pred":"aux","subj":"T576","obj":"T577"},{"id":"R290","pred":"xcomp","subj":"T577","obj":"T575"},{"id":"R291","pred":"punct","subj":"T578","obj":"T577"},{"id":"R292","pred":"prep","subj":"T579","obj":"T575"},{"id":"R293","pred":"pobj","subj":"T580","obj":"T579"},{"id":"R294","pred":"punct","subj":"T581","obj":"T575"},{"id":"R295","pred":"aux","subj":"T582","obj":"T583"},{"id":"R296","pred":"advcl","subj":"T583","obj":"T568"},{"id":"R297","pred":"aux","subj":"T584","obj":"T585"},{"id":"R298","pred":"advcl","subj":"T585","obj":"T583"},{"id":"R299","pred":"punct","subj":"T586","obj":"T587"},{"id":"R300","pred":"appos","subj":"T587","obj":"T585"},{"id":"R301","pred":"punct","subj":"T588","obj":"T587"},{"id":"R302","pred":"cc","subj":"T589","obj":"T585"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"bionlp-st-ge-2016-test-ihmc","denotations":[{"id":"T535","span":{"begin":131,"end":149},"obj":"Entity"},{"id":"T525","span":{"begin":10,"end":30},"obj":"Protein"},{"id":"T523","span":{"begin":145,"end":148},"obj":"Entity"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"DLUT931","denotations":[{"id":"T399","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"BioNLP16_Messiy","denotations":[{"id":"T449","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"BioNLP16_DUT","denotations":[{"id":"T357","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T396","span":{"begin":10,"end":30},"obj":"http://www.uniprot.org/uniprot/P04637"},{"id":"T391","span":{"begin":27,"end":30},"obj":"http://www.uniprot.org/uniprot/P04637"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"bionlp-st-ge-2016-test-proteins","denotations":[{"id":"T120","span":{"begin":27,"end":30},"obj":"Protein"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"pmc-enju-pas","denotations":[{"id":"T203","span":{"begin":150,"end":153},"obj":"CC"},{"id":"T202","span":{"begin":148,"end":149},"obj":"-RRB-"},{"id":"T201","span":{"begin":145,"end":148},"obj":"NN"},{"id":"T200","span":{"begin":144,"end":145},"obj":"-LRB-"},{"id":"T199","span":{"begin":131,"end":143},"obj":"NN"},{"id":"T198","span":{"begin":128,"end":130},"obj":"TO"},{"id":"T197","span":{"begin":117,"end":127},"obj":"NN"},{"id":"T196","span":{"begin":114,"end":116},"obj":"TO"},{"id":"T195","span":{"begin":112,"end":113},"obj":"-COMMA-"},{"id":"T194","span":{"begin":108,"end":112},"obj":"NN"},{"id":"T193","span":{"begin":105,"end":107},"obj":"IN"},{"id":"T192","span":{"begin":103,"end":104},"obj":"-COMMA-"},{"id":"T191","span":{"begin":93,"end":103},"obj":"VB"},{"id":"T190","span":{"begin":90,"end":92},"obj":"TO"},{"id":"T189","span":{"begin":82,"end":89},"obj":"VB"},{"id":"T188","span":{"begin":78,"end":81},"obj":"CC"},{"id":"T187","span":{"begin":76,"end":77},"obj":"-RRB-"},{"id":"T186","span":{"begin":72,"end":76},"obj":"NN"},{"id":"T185","span":{"begin":71,"end":72},"obj":"-LRB-"},{"id":"T184","span":{"begin":57,"end":70},"obj":"NN"},{"id":"T183","span":{"begin":54,"end":56},"obj":"IN"},{"id":"T182","span":{"begin":46,"end":53},"obj":"VB"},{"id":"T181","span":{"begin":35,"end":45},"obj":"RB"},{"id":"T180","span":{"begin":31,"end":34},"obj":"VB"},{"id":"T179","span":{"begin":27,"end":30},"obj":"NN"},{"id":"T178","span":{"begin":16,"end":26},"obj":"NN"},{"id":"T177","span":{"begin":10,"end":15},"obj":"NN"}],"relations":[{"id":"R38","pred":"arg1Of","subj":"T179","obj":"T177"},{"id":"R39","pred":"arg1Of","subj":"T179","obj":"T178"},{"id":"R40","pred":"arg1Of","subj":"T179","obj":"T180"},{"id":"R41","pred":"arg2Of","subj":"T179","obj":"T182"},{"id":"R42","pred":"arg1Of","subj":"T179","obj":"T189"},{"id":"R43","pred":"arg1Of","subj":"T179","obj":"T191"},{"id":"R44","pred":"arg2Of","subj":"T182","obj":"T180"},{"id":"R45","pred":"arg1Of","subj":"T182","obj":"T181"},{"id":"R46","pred":"arg1Of","subj":"T182","obj":"T183"},{"id":"R47","pred":"arg1Of","subj":"T182","obj":"T188"},{"id":"R48","pred":"arg2Of","subj":"T184","obj":"T183"},{"id":"R49","pred":"arg1Of","subj":"T184","obj":"T185"},{"id":"R50","pred":"arg2Of","subj":"T186","obj":"T185"},{"id":"R51","pred":"arg3Of","subj":"T187","obj":"T185"},{"id":"R52","pred":"arg2Of","subj":"T189","obj":"T188"},{"id":"R53","pred":"arg2Of","subj":"T191","obj":"T189"},{"id":"R54","pred":"arg1Of","subj":"T191","obj":"T190"},{"id":"R55","pred":"arg1Of","subj":"T191","obj":"T192"},{"id":"R56","pred":"arg1Of","subj":"T191","obj":"T193"},{"id":"R57","pred":"arg1Of","subj":"T191","obj":"T195"},{"id":"R58","pred":"arg1Of","subj":"T191","obj":"T196"},{"id":"R59","pred":"arg2Of","subj":"T194","obj":"T193"},{"id":"R60","pred":"arg1Of","subj":"T197","obj":"T198"},{"id":"R61","pred":"arg1Of","subj":"T197","obj":"T203"},{"id":"R62","pred":"arg2Of","subj":"T199","obj":"T198"},{"id":"R63","pred":"arg1Of","subj":"T199","obj":"T200"},{"id":"R64","pred":"arg2Of","subj":"T201","obj":"T200"},{"id":"R65","pred":"arg3Of","subj":"T202","obj":"T200"},{"id":"R66","pred":"arg2Of","subj":"T203","obj":"T196"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"GO-BP","denotations":[{"id":"T137","span":{"begin":10,"end":26},"obj":"http://purl.obolibrary.org/obo/GO_0051726"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"sentences","denotations":[{"id":"T2","span":{"begin":1,"end":9},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}

{"project":"simple1","denotations":[{"id":"T150","span":{"begin":27,"end":30},"obj":"Protein"}],"text":"\nAbstract\nTumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeu"}